There is evidence that cytotoxic T lymphocytes (T cells) participate in controlling tumor growth and that they can be harnessed to use the body's immune system to treat cancer. One study investigated the use of a T cell-engaging antibody, blinatumomab, to recruit T cells to control tumor growth. The data below are T cell counts (1000 per microliter) at baseline (beginning of the study) and after 20 days on blinatumomab for 6 subjects in the study. The difference (after 20 days minus baseline) is the response variable.

Baseline0.040.0200.020.280.38After 20 days0.08000.051.120.34Difference0.04-0.0200.030.84-0.04

Do the data give evidence at the 2 % level that the mean count of T cells is higher after 20 days on blinatumomab?

The test statistic is t =(

0.001)

NoYes